Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder.

Curtin K, Fleckenstein AE, Keeshin BR, Yurgelun-Todd DA, Renshaw PF, Smith KR, Hanson GR.

Neuropsychopharmacology. 2018 Dec;43(13):2548-2555. doi: 10.1038/s41386-018-0207-5. Epub 2018 Sep 12.

PMID:
30209407
2.

Brain Slice Staining and Preparation for Three-Dimensional Super-Resolution Microscopy.

German CL, Gudheti MV, Fleckenstein AE, Jorgensen EM.

Methods Mol Biol. 2017;1663:153-162. doi: 10.1007/978-1-4939-7265-4_13.

3.

Sex differences in neurotensin and substance P following nicotine self-administration in rats.

Pittenger ST, Swalve N, Chou S, Smith MD, Hoonakker AJ, Pudiak CM, Fleckenstein AE, Hanson GR, Bevins RA.

Synapse. 2016 Aug;70(8):336-46. doi: 10.1002/syn.21907. Epub 2016 May 4.

4.

Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors.

Baladi MG, Nielsen SM, McIntosh JM, Hanson GR, Fleckenstein AE.

Behav Pharmacol. 2016 Aug;27(5):422-30. doi: 10.1097/FBP.0000000000000215.

5.

An acute, epitope-specific modification in the dopamine transporter associated with methamphetamine-induced neurotoxicity.

Fricks-Gleason AN, German CL, Hoonakker AJ, Friend DM, Ganesh KK, Carver AS, Hanson GR, Fleckenstein AE, Keefe KA.

Synapse. 2016 Apr;70(4):139-46. doi: 10.1002/syn.21891. Epub 2016 Feb 15.

PMID:
26799527
6.

Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.

German CL, Baladi MG, McFadden LM, Hanson GR, Fleckenstein AE.

Pharmacol Rev. 2015 Oct;67(4):1005-24. doi: 10.1124/pr.114.010397. Review.

7.

Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits.

Vieira-Brock PL, McFadden LM, Nielsen SM, Ellis JD, Walters ET, Stout KA, McIntosh JM, Wilkins DG, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2015 Dec;355(3):463-72. doi: 10.1124/jpet.114.221945. Epub 2015 Sep 21.

8.

Nicotine Administration Attenuates Methamphetamine-Induced Novel Object Recognition Deficits.

Vieira-Brock PL, McFadden LM, Nielsen SM, Smith MD, Hanson GR, Fleckenstein AE.

Int J Neuropsychopharmacol. 2015 Jul 11;18(12). pii: pyv073. doi: 10.1093/ijnp/pyv073.

9.

Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.

McFadden LM, Vieira-Brock PL, Hanson GR, Fleckenstein AE.

Neuropharmacology. 2015 Jun;93:146-54. doi: 10.1016/j.neuropharm.2015.01.013. Epub 2015 Jan 31.

10.

Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment.

Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR.

Drug Alcohol Depend. 2015 Jan 1;146:30-8. doi: 10.1016/j.drugalcdep.2014.10.027. Epub 2014 Nov 16.

11.

Prior methylphenidate self-administration alters the subsequent reinforcing effects of methamphetamine in rats.

Baladi MG, Nielsen SM, Umpierre A, Hanson GR, Fleckenstein AE.

Behav Pharmacol. 2014 Dec;25(8):758-65. doi: 10.1097/FBP.0000000000000094.

12.

Mephedrone alters basal ganglia and limbic dynorphin systems.

German CL, Alburges ME, Hoonakker AJ, Fleckenstein AE, Hanson GR.

Synapse. 2014 Dec;68(12):634-640. doi: 10.1002/syn.21778. Epub 2014 Sep 8.

13.

Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia.

Baladi MG, Newman AH, Nielsen SM, Hanson GR, Fleckenstein AE.

Eur J Pharmacol. 2014 Jun 5;732:105-10. doi: 10.1016/j.ejphar.2014.03.023. Epub 2014 Mar 28.

14.

Mephedrone alters basal ganglia and limbic neurotensin systems.

German CL, Hoonakker AH, Fleckenstein AE, Hanson GR.

J Neurochem. 2014 Aug;130(3):402-7. doi: 10.1111/jnc.12727. Epub 2014 Apr 19.

15.

Methamphetamine self-administration attenuates hippocampal serotonergic deficits: role of brain-derived neurotrophic factor.

McFadden LM, Vieira-Brock PL, Hanson GR, Fleckenstein AE.

Int J Neuropsychopharmacol. 2014 Aug;17(8):1315-20. doi: 10.1017/S1461145714000327. Epub 2014 Mar 20.

16.

Iptakalim attenuates self-administration and acquired goal-tracking behavior controlled by nicotine.

Charntikov S, Swalve N, Pittenger S, Fink K, Schepers S, Hadlock GC, Fleckenstein AE, Hu G, Li M, Bevins RA.

Neuropharmacology. 2013 Dec;75:138-44. doi: 10.1016/j.neuropharm.2013.07.019. Epub 2013 Aug 2. Erratum in: Neuropharmacology. 2016 Feb;101():590. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

17.

Bath salts and synthetic cathinones: an emerging designer drug phenomenon.

German CL, Fleckenstein AE, Hanson GR.

Life Sci. 2014 Feb 27;97(1):2-8. doi: 10.1016/j.lfs.2013.07.023. Epub 2013 Aug 2. Review.

18.

The effects of methamphetamine self-administration on cortical monoaminergic deficits induced by subsequent high-dose methamphetamine administrations.

McFadden LM, Hanson GR, Fleckenstein AE.

Synapse. 2013 Dec;67(12):875-81. doi: 10.1002/syn.21696. Epub 2013 Jul 27.

19.

Age-related differences in the disposition of nicotine and metabolites in rat brain and plasma.

Vieira-Brock PL, Andrenyak DM, Nielsen SM, Fleckenstein AE, Wilkins DG.

Nicotine Tob Res. 2013 Nov;15(11):1839-48. doi: 10.1093/ntr/ntt067. Epub 2013 Jun 4.

20.

Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization.

German CL, Hanson GR, Fleckenstein AE.

J Neurochem. 2012 Oct;123(2):288-97. doi: 10.1111/j.1471-4159.2012.07875.x. Epub 2012 Aug 23.

21.

Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations.

McFadden LM, Hunt MM, Vieira-Brock PL, Muehle J, Nielsen SM, Allen SC, Hanson GR, Fleckenstein AE.

Drug Alcohol Depend. 2012 Nov 1;126(1-2):87-94. doi: 10.1016/j.drugalcdep.2012.04.020. Epub 2012 May 28.

22.

Methamphetamine self-administration acutely decreases monoaminergic transporter function.

McFadden LM, Stout KA, Vieira-Brock PL, Allen SC, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE.

Synapse. 2012 Mar;66(3):240-5. doi: 10.1002/syn.21506. Epub 2011 Dec 13.

23.

Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.

McFadden LM, Hadlock GC, Allen SC, Vieira-Brock PL, Stout KA, Ellis JD, Hoonakker AJ, Andrenyak DM, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2012 Feb;340(2):295-303. doi: 10.1124/jpet.111.188433. Epub 2011 Oct 27.

24.

Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry.

Vieira-Brock PL, Miller EI, Nielsen SM, Fleckenstein AE, Wilkins DG.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Nov 15;879(30):3465-74. doi: 10.1016/j.jchromb.2011.09.026. Epub 2011 Sep 18.

25.

4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.

Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2011 Nov;339(2):530-6. doi: 10.1124/jpet.111.184119. Epub 2011 Aug 2.

26.

Ephedrine decreases vesicular monoamine transporter-2 function.

Ellis JD, German CL, Birdsall E, Hanson JE, Crosby MA, Rowley SD, Sawada NA, West JN, Hanson GR, Fleckenstein AE.

Synapse. 2011 May;65(5):449-51. doi: 10.1002/syn.20896. No abstract available.

27.

Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment.

Alburges ME, Hoonakker AJ, Horner KA, Fleckenstein AE, Hanson GR.

J Neurochem. 2011 May;117(3):470-8. doi: 10.1111/j.1471-4159.2011.07215.x. Epub 2011 Mar 15.

28.

Ex vivo identification of protein-protein interactions involving the dopamine transporter.

Hadlock GC, Nelson CC, Baucum AJ 2nd, Hanson GR, Fleckenstein AE.

J Neurosci Methods. 2011 Mar 30;196(2):303-7. doi: 10.1016/j.jneumeth.2011.01.023. Epub 2011 Feb 1.

29.

Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration.

McFadden LM, Hoonakker AJ, Vieira-Brock PL, Stout KA, Sawada NM, Ellis JD, Allen SC, Walters ET, Nielsen SM, Gibb JW, Alburges ME, Wilkins DG, Hanson GR, Fleckenstein AE.

Synapse. 2011 Aug;65(8):771-7. doi: 10.1002/syn.20902. Epub 2011 Mar 21.

30.

Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia.

Frankel PS, Hoonakker AJ, Alburges ME, McDougall JW, McFadden LM, Fleckenstein AE, Hanson GR.

J Pharmacol Exp Ther. 2011 Mar;336(3):809-15. doi: 10.1124/jpet.110.176610. Epub 2010 Dec 2.

31.

Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.

Chu PW, Hadlock GC, Vieira-Brock P, Stout K, Hanson GR, Fleckenstein AE.

J Neurochem. 2010 Oct;115(2):325-32. doi: 10.1111/j.1471-4159.2010.06922.x. Epub 2010 Aug 25.

32.

Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.

Hadlock GC, Chu PW, Walters ET, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2010 Oct;335(1):207-12. doi: 10.1124/jpet.110.166660. Epub 2010 Jul 9.

33.

Measurement of plasmalemmal dopamine transport, vesicular dopamine transport, and K(+)-stimulated dopamine release in frozen rat brain tissue.

Volz TJ, Farnsworth SJ, Hanson GR, Fleckenstein AE.

J Neurosci Methods. 2009 Jun 15;180(2):317-20. doi: 10.1016/j.jneumeth.2009.03.015. Epub 2009 Mar 28.

34.

Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment.

Hanson JE, Birdsall E, Seferian KS, Crosby MA, Keefe KA, Gibb JW, Hanson GR, Fleckenstein AE.

Eur J Pharmacol. 2009 Apr 1;607(1-3):68-73.

35.

Mechanisms underlying methamphetamine-induced dopamine transporter complex formation.

Hadlock GC, Baucum AJ 2nd, King JL, Horner KA, Cook GA, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2009 Apr;329(1):169-74. doi: 10.1124/jpet.108.145631. Epub 2009 Jan 13.

36.

Cocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activation.

Farnsworth SJ, Volz TJ, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2009 Mar;328(3):807-12. doi: 10.1124/jpet.108.146159. Epub 2008 Nov 26.

37.

Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity.

Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE.

Synapse. 2009 Feb;63(2):147-51. doi: 10.1002/syn.20580.

38.

Method development and validation of an in vitro model of the effects of methylphenidate on membrane-associated synaptic vesicles.

Volz TJ, Farnsworth SJ, Hanson GR, Fleckenstein AE.

J Neurosci Methods. 2009 Feb 15;177(1):177-82. doi: 10.1016/j.jneumeth.2008.10.004. Epub 2008 Oct 17.

39.

Methylphenidate-induced alterations in synaptic vesicle trafficking and activity.

Volz TJ, Farnsworth SJ, Hanson GR, Fleckenstein AE.

Ann N Y Acad Sci. 2008 Oct;1139:285-90. doi: 10.1196/annals.1432.012.

40.

Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.

Fleckenstein AE, Volz TJ, Hanson GR.

Neuropharmacology. 2009;56 Suppl 1:133-8. doi: 10.1016/j.neuropharm.2008.07.002. Epub 2008 Jul 10. Review.

41.

Differential regional effects of methamphetamine on dopamine transport.

Chu PW, Seferian KS, Birdsall E, Truong JG, Riordan JA, Metcalf CS, Hanson GR, Fleckenstein AE.

Eur J Pharmacol. 2008 Aug 20;590(1-3):105-10. doi: 10.1016/j.ejphar.2008.05.028. Epub 2008 May 28.

42.

Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors.

Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2008 Oct;327(1):161-7. doi: 10.1124/jpet.108.139386. Epub 2008 Jun 30.

43.

Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.

Volz TJ, Farnsworth SJ, King JL, Riddle EL, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2007 Nov;323(2):738-45. Epub 2007 Aug 10.

PMID:
17693585
44.

Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2.

Riddle EL, Hanson GR, Fleckenstein AE.

Eur J Pharmacol. 2007 Sep 24;571(1):25-8. Epub 2007 Jun 5.

45.

Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment.

Volz TJ, Fleckenstein AE, Hanson GR.

Addiction. 2007 Apr;102 Suppl 1:44-8. Review.

PMID:
17493052
46.

The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits.

Volz TJ, Hanson GR, Fleckenstein AE.

J Neurochem. 2007 May;101(4):883-8. Epub 2007 Jan 23. Review.

47.

Persistence of tolerance to methamphetamine-induced monoamine deficits.

Danaceau JP, Deering CE, Day JE, Smeal SJ, Johnson-Davis KL, Fleckenstein AE, Wilkins DG.

Eur J Pharmacol. 2007 Mar 15;559(1):46-54. Epub 2006 Dec 1.

PMID:
17239369
48.

New insights into the mechanism of action of amphetamines.

Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR.

Annu Rev Pharmacol Toxicol. 2007;47:681-98. Review.

PMID:
17209801
49.

Age-dependent effects of methamphetamine on VMAT-2.

Rau KS, Truong JG, Wilkins DG, Fleckenstein AE, Hanson GR.

Ann N Y Acad Sci. 2006 Aug;1074:154-9.

PMID:
17105913
50.

Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function.

Volz TJ, Hanson GR, Fleckenstein AE.

Synapse. 2006 Nov;60(6):474-7.

PMID:
16897727

Supplemental Content

Loading ...
Support Center